SCYNEXIS to Present SCY-247 Preclinical Data at IDWeek 2024
JERSEY CITY, N.J., Oct. 03, 2024 — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology firm known for creating cutting-edge treatments to combat challenging and drug-resistant infections, revealed upcoming presentations of preclinical efficacy and pharmacokinetic data concerning its second-generation antifungal candidate, SCY-247, at IDWeek 2024 in Los Angeles, CA, from October 16-19, 2024.
Details of the presentations are provided below:
Oral Presentation:
Title: Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections
Session: Mycology Matters: Insights into Fungal Infections
Date/Time: Thursday, October 17, 2024, at 10:45 AM PDT
Location: Los Angeles Convention Center, Room 403 B
Presenting Author: David A. Angulo, M.D., President and CEO of SCYNEXIS
Poster Presentation:
Title: SCY-247: A Second-generation IV/Oral Triterpenoid Antifungal with Extensive Tissue Distribution and Pharmacokinetics, and Low Drug-Drug Interaction Potential
Session: New Drug Development
Date/Time: Friday, October 18, 2024, at 12:15 – 1:30 PM PDT
Location: Los Angeles Convention Center, Halls JK
Presenting Author: David A. Angulo, M.D., President and CEO of SCYNEXIS
About SCY-247
SCY-247 is a next-generation antifungal agent belonging to a unique class of glucan synthase inhibitors known as triterpenoids (fungerps). This compound is designed to counter the significant threat posed by antimicrobial resistance (AMR) in systemic fungal diseases, which often have high mortality rates. The triterpenoid class represents the first new category of antifungals approved since 2001, merging the known activity of glucan synthase inhibitors with the adaptability of oral and intravenous (IV) formulations. SCY-247 is currently in the pre-IND development stage and has shown broad-spectrum antifungal efficacy in both in vitro and in vivo models, including effectiveness against multidrug-resistant fungal pathogens. SCYNEXIS expects that the U.S. Food and Drug Administration (FDA) may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track designations for both its IV and oral formulations.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to developing groundbreaking medicines to help patients worldwide overcome and prevent challenging infections that are increasingly becoming drug-resistant. The company is advancing its proprietary antifungal platform, known as “fungerps.” The first drug in this new class, ibrexafungerp, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) in June 2021 for treating vulvovaginal candidiasis (VVC), with a second indication approved in November 2022 for reducing recurrent VVC. Late-stage clinical trials are in progress to assess ibrexafungerp's efficacy in treating life-threatening invasive fungal infections in hospitalized patients. Additional antifungal candidates from this innovative class are in preclinical and discovery phases, including SCY-247.
SCYNEXIS is dedicated to helping millions of patients by developing superior antifungal solutions that confront the growing issue of drug-resistant infections.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
